Breaking Business News: Crown Laboratories to Buy Revance Therapeutics in $924 Million Merger Deal
The Dermatology Digest
AUGUST 12, 2024
Combined company’s flagship brands to include daxibotulinumtoxinA (Daxxify), the RHA filler Collection, SkinPen, PanOxyl, Blue Lizard, and StriVectin. The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price.
Let's personalize your content